Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin

Journal of Medicinal Chemistry

Volumn 55, Issue 9, 2012, Pages 4516-4520

  Legigan, Thibaut ^a   Clarhaut, Jonathan ^b   Renoux, Brigitte ^a   Tranoy Opalinski, Isabelle ^a   Monvoisin, Arnaud ^a   Berjeaud, Jean Marc ^a   Guilhot, François ^b   Papot, Sébastien ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA GLUCURONIDASE; DOXORUBICIN; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; GLYCOSIDES; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALEIMIDES; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; PRODRUGS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861037988     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300348r     Document Type: Article

References (30)

1. L. F. Tietze was one of the first researchers to propose the use of glucuronide prodrugs for selective cancer chemotherapy: Tietze, L.; Seele, R.; Leiting, B.; Krach, T. Stereoselective synthesis of (1-alkoxyalkyl) alpha- and beta- d -glucopyranosiduronates (acetal-glucopyranosiduronates): a new approach to specific cytostatics for the treatment of cancer Carbohydr. Res. 1988, 180, 253-262
2. de Graaf, M.; Boven, E.; Scheeren, H. W.; Haisma, H. J.; Pinedo, H. M. Beta-glucuronidase-mediated drug release Curr. Pharm. Des. 2002, 8, 1391-1403 (Pubitemid 34591354)
3. Chen, X.; Wu, B.; Wang, P. G. Glucuronides in anti-cancer therapy Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 139-150 (Pubitemid 36221734)
4. Grinda, M.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Papot, S. A self-immolative dendritic glucuronide prodrug of doxorubicin MedChemComm 2012, 3, 68-70
5. Tietze, L. F.; Schmuck, K.; Schuster, H. J.; Müller, M.; Schuberth, I. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT Chem. - Eur. J. 2011, 17, 1922-1929
6. Grinda, M.; Clarhaut, J.; Tranoy-Opalinski, I.; Renoux, B.; Monvoisin, A.; Cronier, L.; Papot, S. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier ChemMedChem 2011, 6, 2137-2141
7. Renoux, B.; Legigan, T.; Bensalma, S.; Chadéneau, C.; Muller, J.-M.; Papot, S. A new cyclopamine glucuronide prodrug with improved kinetics of drug release Org. Biomol. Chem. 2011, 9, 8459-8464
8. Connors, T. A.; Whisson, M. E. Nature 1966, 210, 866-867
9. Bosslet, K.; Czech, J.; Hoffmann, D. Tumor Target. 1995, 1, 45-50
10. Houba, P. H. J.; Boven, E.; Erkelens, C. A. M.; Leenders, R. G. G.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts Br. J. Cancer 1998, 78, 1600-1606 (Pubitemid 28550045)
11. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res. 1998, 58, 1195-1201 (Pubitemid 28183208)
12. Woessner, R.; An, Z.; Li, X.; Hoffman, R. M.; Dix, R.; Bitonti, A. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and β-glucuronidase-activated prodrug (HMR 1826) Anticancer Res. 2000, 20, 2289-2296 (Pubitemid 30614428)
13. Houba, P. H. J.; Boven, E.; Van Der Meulen-Muileman, I. H.; Leenders, R. G. G.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer Br. J. Cancer 2001, 84, 550-557 (Pubitemid 32215885)
14. Juan, T. Y.; Roffler, S. R.; Hou, H. S.; Huang, S. M.; Chen, K. C.; Leu, Y. L.; Prijovich, Z. M.; Yu, C. P.; Wu, C. C.; Sun, G. H.; Cha, T. L. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity Clin. Cancer Res. 2009, 15, 4600-4611
15. Enhanced permeability and retention: Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 2011, 63, 136-151
16. Review on albumin as a drug carrier: Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183
17. Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Druckes, P.; Esser, N.; Drevs, J.; Rognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 2002, 45, 5523-5533 (Pubitemid 35424970)
18. Warnecke, A.; Fichtner, I.; Garmann, D.; Jaehde, U.; Kratz, F. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs Bioconjugate Chem. 2004, 15, 1349-1359 (Pubitemid 39552025)
19. Schmid, B.; Chung, D. E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716 (Pubitemid 47010789)
20. Graeser, R.; Esser, N.; Unger, H.; Fichtner, I.; Zhu, A.; Unger, C.; Kratz, F. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model Invest. New Drugs 2010, 28, 14-19
21. Elsadek, B.; Graeser, R.; Warnecke, A.; Unger, C.; Saleem, T.; El-Melegy, N.; Madkor, H.; Kratz, F. Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen ACS Med. Chem. Lett. 2010, 1, 234-238
22. Elsadek, B.; Graeser, R.; Esser, N.; Schafer-Obodozie, C.; Abu Ajaj, K.; Unger, C.; Warnecke, A.; Saleem, T.; El-Melegy, N.; Madkor, H.; Kratz, F. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study Eur. J. Cancer 2010, 46, 3434-3444
23. Unger, C.; Haring, B.; Medinger, M.; Drevs, J.; Steinbild, S.; Kratz, F.; Mross, K. Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin Clin. Cancer Res. 2007, 13, 4858-4866 (Pubitemid 47294793)
24. Kratz, F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866 (Pubitemid 46882358)
25. Papot, S.; Tranoy, I.; Tillequin, F.; Florent, J. C.; Gesson, J. P. Design of selectively activated anticancer prodrugs: elimination and cyclization strategies Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 155-85 (Pubitemid 34649872)
26. Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J. P.; Papot, S. Design of self-immolative linkers for tumour-activated prodrug therapy Anti-Cancer Agents Med. Chem. 2008, 8, 618-637
27. The first maleimide-containing glucuronide-linker was described in the following: Jeffrey, S. C.; Andreyka, J. B.; Bernhardt, S. X.; Kissler, K. M.; Kline, T.; Lenox, J. S.; Moser, R. F.; Nguyen, M. T.; Okeley, N. M.; Stone, I. J.; Zhang, X. Q.; Senter, P. D. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates Bioconjugate Chem. 2006, 17, 831-840 (Pubitemid 43794395)
28. Florent, J. C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy J. Med. Chem. 1998, 41, 3572-3581 (Pubitemid 28449340)
29. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 41, 2596-2599 (Pubitemid 34803480)
30. Elimination half-life of HMR 1826 is between 0.4 and 2.6 h: Bosslet, K.; Czech, J.; Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis Cancer Res. 1994, 54, 2151-2159 (Pubitemid 24138689)